Antibiotic Resistance of Pseudomonas aeruginosa in Pneumonia at a Single University Hospital Center in Germany over a 10-Year Period

Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling

(2015) Jürgen B. Bulitta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from U.S. Hospitals

(2014) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa*

(2014) Marin H. Kollef et al.   CRITICAL CARE MEDICINE

Detection of Metallo-Beta Lactamases Among Carbapenem-Resistant Pseudomonas aeruginosa

(2014) Ahmad Farajzadeh Sheikh et al.   Jundishapur Journal of Microbiology

The Pseudomonas aeruginosa Type III Translocon Is Required for Biofilm Formation at the Epithelial Barrier

(2014) Cindy S. Tran et al.   PLoS Pathogens

Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

(2014) Dilip Nathwani et al.   Antimicrobial Resistance and Infection Control

Pneumonia Due to Pseudomonas aeruginosa

(2011) Shigeki Fujitani et al.   CHEST

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

The Pseudomonas aeruginosa opportunistic pathogen and human infections

(2011) Sophie de Bentzmann et al.   ENVIRONMENTAL MICROBIOLOGY

Levofloxacin in the treatment of community-acquired pneumonia

(2010) Ayman M Noreddin et al.   Expert Review of Anti-Infective Therapy

In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy

(2010) Mickaël Riou et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Impact of multidrug-resistantPseudomonas aeruginosainfection on patient outcomes

(2010) Elizabeth B Hirsch et al.   Expert Review of Pharmacoeconomics & Outcomes Research

In Vitro Activity of Colistin (Polymyxin E) against 3,480 Isolates of Gram-Negative Bacilli Obtained from Patients in Canadian Hospitals in the CANWARD Study, 2007-2008

(2009) A. Walkty et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit*

(2009) Andrew F. Shorr   CRITICAL CARE MEDICINE

Current Treatment of Pseudomonal Infections in the Elderly

(2009) Georgios Pappas et al.   DRUGS & AGING

Outcomes of Bacteremia due to Pseudomonas aeruginosa with Reduced Susceptibility to Piperacillin-Tazobactam: Implications on the Appropriateness of the Resistance Breakpoint

(2008) V. H. Tam et al.   CLINICAL INFECTIOUS DISEASES

Fosfomycin: Use Beyond Urinary Tract and Gastrointestinal Infections

(2008) Matthew E. Falagas et al.   CLINICAL INFECTIOUS DISEASES

Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies

(2008) N. Petrosillo et al.   CLINICAL MICROBIOLOGY AND INFECTION

Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia

(2008) A. H. W. Bruns et al.   EUROPEAN RESPIRATORY JOURNAL